Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its Tecnis PureSee intraocular lens (IOL), giving eye surgeons a new lens option for use in cataract surgery.
The company identified Tecnis PureSee as the first FDA-approved extended depth of focus intraocular lens, which maintains contrast sensitivity, an important aspect of visual quality that determines a patient’s ability to differentiate an object from its background.
Tecnis PureSee is designed to decrease patients’ dependence on glasses post-surgery, JNJ said, adding that 97% of users haven’t reported halos, glare, or other visual disturbances following its implantation.
The product expected to launch in the U.S. later this year will be the latest addition to J&J’s (JNJ) Tecnis portfolio of lenses, which includes Tecnis Odyssey IOL, a Full Visual Range IOL, and TECNIS Eyhance IOL, a monofocal IOL.